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SUMMARY Possible modes of transmission of the human papilloma virus 
(HPV) in children include perinatal transmission, sexual transmission, or 
extragenital contact. Conventional treatment options with chemical and 
physical destruction methods can be difficult and painful and often require 
general anesthesia. Imiquimod is a topically active immunomodulatory 
agent that has been shown to successfully treat pediatric anogenital warts. 
We report on a case of extensive anogenital warts in a 18-month-old girl 
who was successfully treated with topical 5% imiquimod cream.
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InTRodUCTIon  
Condyloma acuminatum, i.e. genital warts, are 
caused by infection with the human papilloma virus 
(HPV), mostly by low risk HPV 6 and 11. The incidence 
of anogenital warts in children is unknown but is 
suspected to be on the rise based on the increase in 
adult HPV infections (1). Perinatal infection may occur 
transplacentally via amniotic fluid during gestation 
and delivery, and through direct exposure to cervical 
and genital lesions during birth. In addition to sexual 
abuse, postnatal infections can be acquired through 
heteroinoculation or autoinoculation from nongeni-
tal mucocutaneous HPV sources and fomite transmis-
sion (2). Several studies have demonstrated that HPV 
can be acquired in the neonatal period, persisting in 
some infants for up to 26 months (3). Surgical treat-
ment options include cryotherapy, laser vaporisa-
tion, electrocautery, and excision. These methods are 
painful, often requiring general anesthesia. with re-
currences being common. Nonsurgical approaches in 
children include the use of podophyllotoxin and im-
iquimod. Although some studies demonstrate their 
safety and efficacy, these drugs are not approved for 
use in children under 12 years of age (1,4).
We report on a 18-month-girl with extensive ano-
genital warts who was successfully treated with topi-
cal 5% imiquimod cream. 
CASe RepoRT
A healthy 18-month-old female child was referred 
to our Department of pediatric and adolescent gyne-
cology, Children’s Hospital Zagreb, with a 7-month 
history of anogenital warts. The girl was born by Cae-
sarean section because of pelvic presentation. She 
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was a healthy child until the warts started to grow. 
She was previously unsuccessfully treated with 5-
fluorouracil cream, fluorouracil and salicylic acid solu-
tion, 50% and 80% trichloracetic acid, as well as cryo-
therapy in another institution. The father reported 
genital warts 5-months ago, when he was treated by 
cryotherapy. He was evaluated by our dermatologist, 
and had no evidence of genital warts at the time. The 
mother was also evaluated, but no symptoms of HPV 
infection were found, and she had no history of geni-
tal warts. 
Physical examination of the child was normal ex-
cept for the presence of multiple skin-colored, conflu-
ent verrucous papules affecting the vulva and peri-
anal region (Figure 1). Gynecological examination 
showed no abnormalities. The hymen was intact, and 
there was no evidence of ulcerations or other signs of 
trauma to the vaginal or anal orifices. A biopsy of the 
warts was performed under local anesthesia and low 
risk HPV was confirmed using Digene Hybrid Capture 
II test. The histologic picture was typical for hyperpro-
liferative papilloma, showing abundant koilocytosis 
and being compatible with condyloma. 
The girl was treated with 5% imiquimod cream, 
applied at home to the lesions three times a week, 
before bedtime. After 8 to 10 hours, the cream was 
removed by washing the treated area with mild soap 
and water. The mother and child visited our hospital 
every 3-4 weeks and at every visit, there was evident 
reduction in the number and size of warts. Treatment 
was continued for a total of 11 weeks, during which 
time the lesions cleared almost completely (Figure 2). 
At the end of the imiquimod treatment, the remains 
of three small papules fell down spontaneously 3 
days later, and complete clearance of the lesions was 
achieved. Only one adverse effect was recorded, a 
one-day burning of the perilesional skin. No systemic 
adverse effects were noticed. After eighteen months 
of follow–up there was no evidence of recurrence.
dISCUSSIon
Condylomata acuminata are anogenital warts 
caused by the human papilloma virus (HPV), mostly 
by low risk HPV 6 and 11, but types 1, 2, 16, and 18 
are also found. The highest risk population for HPV 
infection are sexually active young people under 
the age of 26, especially sexually active adolescents. 
Condyloma in the children under the age of 3 years is 
commonly believed to be vertically transmitted from 
a virally infected genital tract or through caretakers 
with hand warts (3). Although genital warts in small 
children may be vertically transmitted, sexual abuse 
must always be ruled out through social history and 
physical examination for signs of abuse (5,6). In our 
case, there was no evidence of sexual abuse on clini-
cal examination, although the girl’s father had been 
treated for genital condyloma several months ago. In 
this case, the probable route of transmission is non-
sexual, close contact with her father in his role as a 
caregiver. 
Diagnosis of anogenital warts is usually made on 
physical examination. A biopsy and HPV detection 
using Digene Hybrid Capture II test can also be done 
to detect the viral type or if the diagnosis is question-
Figure1. Multiple skin-colored, confluent verrucous 
papules in the vulvar and perianal regions, prior to 
treatment.
Figure 2. Total regression of lesions after 11 weeks of 
imiquimod treatment.
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publication 
year
Authors Faculty Age Sex Area duration 
of
therapy
outcome Side effects  no 
recurrence
2001 Gruber and 
Wilkinson
UK 2 years Boy Perianal 5 weeks Cleared Mild pruritus 15 months
2001 Moresi et al. USA <2 years (n=2) 
2-5 years(n=3)























months in  
six patients
2001 Schaen and 
Mercurio
USA 6 months Girl Perianal + 
vulvar
3 weeks Cleared None No date
2003 Mayewski 
et al.
Poland 19 months Boy Perianal 8 weeks Cleared Local erythema 6 months
2007 Campaner 
et al.
Brazil 7 years Girl Perianal + 
vulvar






2010 Masuko Japan 28 months Girl Perianal + 
vulvar






























2012 Leclair et al. Canada 3 years Girl Perianal+ 
groin +glutea
6 weeks Cleared Minor redness 24 months
2013 Our case Croatia 18 month Girl Perianal+
vulvar
11 weeks Cleared Mild local 
burning 
18 months
Table 1. The use of imiquimod 5%  cream for pediatric anogenital warts. Modified table from Masuko et al (8).
able, or when child abuse is suspected. In our patient, 
we have did both diagnostic tests which established 
the diagnosis of condylomata acuminata.
Treatment of lesions resulting from HPV should 
be individualized. The conventional therapy treat-
ment includes chemical and physical destruction of 
the lesions. They often require the use of anesthesia, 
and recurrences of the lesions are common (7). Our 
patient was treated with most of the conventional 
methods, but without any result.
Imiquimod is a topically active immunomodula-
tory agent that induces keratinocytes to produce in-
terferon alfa and other cytokines in order to inhibit 
viral replication. Imiquimod also enhances cell-me-
diated immunity (8). The use of imiquimod for pe-
diatric anogenital warts has been reported to be an 
effective treatment (7,9-11,14). An overview of these 
results was presented by Masuko et al. (8). We have 
modified their table with new cases (Table 1). In these 
studies, duration of treatment was between 2 and 12 
weeks. Duration of therapy in our case was 11 weeks, 
and the rest of three small papules resolved sponta-
neously three days after the therapy with imiquimod 
was finished. Complete clearance of the lesions was 
achieved. Imiquimod treatment has been shown to 
be a successful treatment for condylomata acuminata 
in adults and long-lasting cutaneous warts and mol-
luscum contagiosum in children. Clearance of exter-
nal warts is achieved in 72% to 84% of the cases, and 
local recurrence rates were 5%-19% (12). In case of 
incomplete resolution, some authors suggest that a 
combination of imiquimod and destructive methods 
may play a role in the treatment of extensive condy-
loma (12).
Overall, 5% imiquimod cream is well tolerated. The 
most common adverse reactions include erythema, 
burning, itching, and tenderness, frequently limited 
to application sites. Less than 1% of the cream ap-
plied topically is absorbed systematically. Side effects 
are usually mild and well-tolerated (13). Although the 
treatment in our case lasted 11 weeks, only mild one-
day burning was present.
ConClUSIon 
Therapy with immiquimod has many advantages, 
such as easy, painless application at home, mild side 
effects, and a low recurrence rate. It is safe and toler-
able in children. Disadvantages include the high price 
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of the cream, especially in long term application. Im-
miquimod could be the first line of treatment for ex-
tensive condyloma in children. Despite the excellent 
response to imiquimod, careful long-term follow-up 
is indicated because of the risk of recurrences and un-
known risk of development of anogenital neoplasia.
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